Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals (SUPN) is a US-based specialty pharmaceutical company focused on central nervous system (CNS) disorders. The company commercialises a small portfolio of branded treatments for conditions such as epilepsy, seizure clusters and attention-deficit/hyperactivity disorder (ADHD), and invests in development of new formulations and indications. With a market capitalisation around $3.18bn, Supernus’s revenue depends heavily on a handful of products and successful execution of its pipeline and marketing strategy. Investors should note the typical sector risks: regulatory approval, reimbursement and patent expiry can materially affect sales; competition from generics and larger peers is significant; and clinical setbacks can change outlooks quickly. That said, periodic product launches, label expansions and targeted marketing can support growth. This summary is for general educational purposes only and not personal advice — investors should perform their own research and consider their risk tolerance and investment horizon before taking action.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Supernus Pharmaceuticals stock with a target price of $59.33, indicating growth potential.
Financial Health
Supernus Pharmaceuticals is performing well with strong profits, cash flow, and revenue growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SUPN
Domestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketBeyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Focused CNS Portfolio
Supernus concentrates on central nervous system therapies such as ADHD and epilepsy, which can offer targeted market opportunities though sales hinge on a few key products.
Growth Drivers To Watch
Pipeline progress, label expansions and new launches can drive revenue, but regulatory outcomes and competition may cause performance to vary.
Commercial & Regulatory Risks
Pricing, reimbursement and patent timelines shape profitability; investors should weigh these structural risks alongside potential upside.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
